CY1117735T1 - Σκευασμα αντισωματος - Google Patents

Σκευασμα αντισωματος

Info

Publication number
CY1117735T1
CY1117735T1 CY20161100603T CY161100603T CY1117735T1 CY 1117735 T1 CY1117735 T1 CY 1117735T1 CY 20161100603 T CY20161100603 T CY 20161100603T CY 161100603 T CY161100603 T CY 161100603T CY 1117735 T1 CY1117735 T1 CY 1117735T1
Authority
CY
Cyprus
Prior art keywords
antibody
pharmaceutical preparations
packaging
administration
stable
Prior art date
Application number
CY20161100603T
Other languages
English (en)
Inventor
Joachim Momm
Hans-Joachim Wallny
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117735(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1117735T1 publication Critical patent/CY1117735T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με φαρμακευτικά σκευάσματα, ιδίως με νέα φαρμακευτικά σκευάσματα στα οποία το δραστικό συστατικό περιέχει ανθρώπινα αντισώματα της ανθρώπινης ιντερλευκίνης βήτα I (IL-1β), ιδίως το αντίσωμα ACZ885, με φαρμακευτικά σκευάσματα τα οποία είναι σταθερά και δεν δημιουργούνται συσσωματώματα κατά την αποθήκευση και τη χορήγηση.
CY20161100603T 2008-12-10 2016-06-30 Σκευασμα αντισωματος CY1117735T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation
PCT/EP2009/066675 WO2010066762A1 (en) 2008-12-10 2009-12-09 Antibody formulation
EP09764858.8A EP2376533B1 (en) 2008-12-10 2009-12-09 Antibody formulation

Publications (1)

Publication Number Publication Date
CY1117735T1 true CY1117735T1 (el) 2017-05-17

Family

ID=40637230

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100603T CY1117735T1 (el) 2008-12-10 2016-06-30 Σκευασμα αντισωματος
CY20211101069T CY1124844T1 (el) 2008-12-10 2021-12-07 Φαρμακευτικο σκευασμα αντισωματος

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211101069T CY1124844T1 (el) 2008-12-10 2021-12-07 Φαρμακευτικο σκευασμα αντισωματος

Country Status (32)

Country Link
US (3) US20110236398A1 (el)
EP (4) EP2196476A1 (el)
JP (5) JP6143416B2 (el)
KR (2) KR20170044211A (el)
CN (3) CN102245639B (el)
AU (1) AU2009324371B2 (el)
BR (1) BRPI0922730A2 (el)
CA (1) CA2745938C (el)
CL (1) CL2011001406A1 (el)
CO (1) CO6361952A2 (el)
CY (2) CY1117735T1 (el)
DK (2) DK2376533T3 (el)
EC (1) ECSP11011192A (el)
ES (2) ES2579835T3 (el)
HK (1) HK1159130A1 (el)
HR (2) HRP20211899T1 (el)
HU (2) HUE028408T2 (el)
IL (3) IL264316B2 (el)
LT (1) LT3072906T (el)
MA (1) MA33023B1 (el)
MX (1) MX2011006242A (el)
MY (2) MY166050A (el)
NZ (1) NZ592918A (el)
PE (1) PE20120342A1 (el)
PL (2) PL3072906T3 (el)
PT (2) PT2376533T (el)
RU (2) RU2745601C2 (el)
SI (2) SI2376533T1 (el)
SM (1) SMT201600222B (el)
TN (1) TN2011000229A1 (el)
WO (1) WO2010066762A1 (el)
ZA (1) ZA201103362B (el)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
KR20120130757A (ko) 2010-02-26 2012-12-03 노보 노르디스크 에이/에스 안정한 항체 함유 조성물
CA2976671C (en) 2010-03-01 2021-01-12 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CA2800188A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103282042B (zh) 2010-09-17 2014-12-10 巴克斯特国际公司 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TWI700093B (zh) 2011-03-16 2020-08-01 法商賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
WO2013082282A1 (en) 2011-12-02 2013-06-06 lNOVARTIS AG Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease.
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
MX370199B (es) * 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
KR102459666B1 (ko) * 2012-03-16 2022-10-27 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP3501550A1 (en) 2012-04-02 2019-06-26 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
IN2015KN00657A (el) * 2012-09-20 2015-07-17 Morphosys Ag
WO2014078502A1 (en) * 2012-11-16 2014-05-22 Novartis Ag Use of il-1 beta binding antibodies for treating peripheral arterial disease
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016515515A (ja) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 抗プロラクチン受容体抗体製剤
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JP6707469B2 (ja) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
RU2017107847A (ru) * 2014-09-03 2018-10-03 Медиммун Лимитед Стабильный состав на основе антитела к il-4r-альфа
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
ES2823279T3 (es) 2015-12-07 2021-05-06 Merck Patent Gmbh Formulación farmacéutica acuosa que comprende el anticuerpo anti-PD-1 Avelumab
EP3487584A1 (en) * 2016-07-21 2019-05-29 Novartis AG Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
US10961314B2 (en) * 2016-09-27 2021-03-30 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition comprising an anti-IL-6 receptor antibody
BR112019010064A2 (pt) 2016-11-18 2019-10-01 Astellas Pharma Inc novo fragmento fab do anticorpo muc1 anti-humano
TW201904993A (zh) * 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CN111315412A (zh) * 2017-09-13 2020-06-19 诺华股份有限公司 Il-1b结合抗体用于治疗酒精性肝炎的用途
KR20210074284A (ko) 2018-10-10 2021-06-21 아스텔라스세이야쿠 가부시키가이샤 표지부-항인간 항체 Fab 프래그먼트 복합체를 포함하는 의약 조성물
MA55033A (fr) * 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
US20240052026A1 (en) * 2020-12-22 2024-02-15 Bio-Thera Solutions, Ltd. Stable antibody formulation, preparation method therefor, and applications thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PE20020132A1 (es) 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
EP1336410A4 (en) * 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CN1798575A (zh) * 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
TW200638943A (en) * 2005-01-28 2006-11-16 Wyeth Corp Stabilized liquid polypeptide formulations
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1871806A2 (en) * 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC ANTI-MAdCAM ANTIBODY COMPOSITIONS
JP5053264B2 (ja) * 2005-05-19 2012-10-17 アムジェン インコーポレイテッド 抗体の安定性を増加させるための組成物および方法
PT1940465E (pt) 2005-10-26 2012-10-03 Novartis Ag Nova utilização para compostos de il-1 beta
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
EP2094729A1 (en) * 2006-12-11 2009-09-02 F.Hoffmann-La Roche Ag Abeta antibody parenteral formulation
CA2681743A1 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
LT3072906T (lt) 2021-12-27
RU2011127913A (ru) 2013-01-20
PL3072906T3 (pl) 2022-01-24
RU2015132431A3 (el) 2018-12-24
EP3792282A1 (en) 2021-03-17
JP2020203889A (ja) 2020-12-24
SI2376533T1 (sl) 2016-07-29
JP6143416B2 (ja) 2017-06-07
MY166050A (en) 2018-05-22
PT2376533T (pt) 2016-07-13
RU2745601C2 (ru) 2021-03-29
JP2018168158A (ja) 2018-11-01
IL212922A0 (en) 2011-07-31
CL2011001406A1 (es) 2012-03-30
SMT201600222B (it) 2016-08-31
CO6361952A2 (es) 2012-01-20
HRP20211899T1 (hr) 2022-03-04
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
KR101762966B1 (ko) 2017-07-31
IL276622A (en) 2020-09-30
HUE028408T2 (en) 2016-12-28
US20110236398A1 (en) 2011-09-29
KR20120009421A (ko) 2012-01-31
HUE056626T2 (hu) 2022-02-28
IL264316A (en) 2019-02-28
BRPI0922730A2 (pt) 2018-11-06
HRP20160754T1 (hr) 2016-08-12
TN2011000229A1 (en) 2012-12-17
DK2376533T3 (en) 2016-06-27
IL212922B (en) 2019-02-28
CN104399076B (zh) 2021-09-14
MA33023B1 (fr) 2012-02-01
PE20120342A1 (es) 2012-04-24
EP2376533A1 (en) 2011-10-19
AU2009324371A1 (en) 2011-06-23
MX2011006242A (es) 2011-06-24
IL264316B1 (en) 2023-09-01
SI3072906T1 (sl) 2022-01-31
RU2563179C2 (ru) 2015-09-20
JP7286595B2 (ja) 2023-06-05
PL2376533T3 (pl) 2016-09-30
CA2745938C (en) 2018-04-24
AU2009324371B2 (en) 2013-10-10
JP2015231997A (ja) 2015-12-24
JP2023109938A (ja) 2023-08-08
PT3072906T (pt) 2021-12-14
KR20170044211A (ko) 2017-04-24
US20200384108A1 (en) 2020-12-10
EP2196476A1 (en) 2010-06-16
EP2376533B1 (en) 2016-03-30
CN102245639A (zh) 2011-11-16
CN104399076A (zh) 2015-03-11
ECSP11011192A (es) 2011-08-31
IL264316B2 (en) 2024-01-01
RU2015132431A (ru) 2018-12-24
EP3072906A1 (en) 2016-09-28
CY1124844T1 (el) 2022-11-25
DK3072906T3 (da) 2021-12-13
ES2579835T3 (es) 2016-08-17
ES2900624T3 (es) 2022-03-17
US8623367B2 (en) 2014-01-07
CN114225022A (zh) 2022-03-25
JP2012511540A (ja) 2012-05-24
CN102245639B (zh) 2014-12-24
EP3072906B1 (en) 2021-09-08
HK1159130A1 (zh) 2012-07-27
ZA201103362B (en) 2012-01-25
WO2010066762A1 (en) 2010-06-17
CA2745938A1 (en) 2010-06-17
US20120315285A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
CY1117735T1 (el) Σκευασμα αντισωματος
CY1125697T1 (el) Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων
CY1123909T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
AR109513A2 (es) Un complejo proteico, un método para preparar un complejo proteico y una composición farmaceutica que lo comprende
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
CY1123739T1 (el) Αντισωματα anti-cd38
CY1121233T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r)
CY1118735T1 (el) Παραγωγα βενζιμιδαζολο-προλινης
CY1113869T1 (el) Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
CY1118080T1 (el) Σωματιδια απελευθερωσης που ομοιαζουν με ιικα σωματιδια για αυτοαντιγραφικα rna μορια
SG11201907321TA (en) Anti-gprc5d antibody and molecule comprising the antibody
CY1118373T1 (el) Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος
MX2018014228A (es) Proteina de union de albumina sérica de dominio unico.
CY1116302T1 (el) Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CY1110926T1 (el) Υποκατεστημενες πυραζολο πυριδινες, συνθεσεις που τις περιεχουν, διαδικασια παρασκευης και χρηση
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
PH12015502591B1 (en) Stable formulations of immunoglobulin single variable domains and uses thereof
CY1119968T1 (el) Συνθεσεις καινοτομων καλλυντικων και/ή φαρμακευτικων προϊοντων και χρησεις αυτων
WO2015095301A3 (en) Cytotoxic peptides and conjugates thereof
CY1112682T1 (el) Ενεργες παραλλαγες της πρωτεϊνης προσδεσης il-18 και ιατρικες χρησεις αυτων
CY1115082T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων
CY1117288T1 (el) Παραγωγα 2-οξο-1-πυρρολιδινυλ ιμιδαζοθειαδιαζολης
CY1119036T1 (el) Νεοι αγωνιστες του υποδοχεα τυπου 2 της αγγειοτενσινης (ατ2) και χρησεις τους
PA8594801A1 (es) Formulaciones farmaceuticas liquidas de palanosetron